[ Price : $8.95]
Agios Pharmaceuticals says it plans to seek accelerated approval for mitapivat in sickle cell disease, following a pre-submission ...[ Price : $8.95]
FDA issues a safety alert warning that patients taking Amgens Tavneos (avacopan) for a rare autoimmune condition may face a risk o...[ Price : $8.95]
Looking to modernize drug and biologic development, FDA seeks industry and public input on how to expand the use of digital health...[ Price : $8.95]
Scholar Rock resubmits its BLA for apitegromab, an investigational therapy for children and adults with Spinal Muscular Atrophy.[ Price : $8.95]
FDA inspection records show that some generic drug manufacturers are routinely failing to carry out basic safety and quality check...[ Price : $8.95]
In a coordinated action, CBER issues four untitled letters targeting promotional materials for leading T-cell therapies and signal...[ Price : $8.95]
FDA accepts for priority review a Praxis Precision Medicines NDA for relutrigine, an investigational therapy targeting rare geneti...[ Price : $8.95]
FDA approves a higher-dose regimen of Biogens Spinraza (nusinersen) for treating spinal muscular atrophy.